Alpha-4 beta-2 neuronal nicotinic acetylcholine receptor (α4β2 nAChR)

The alpha-4 beta-2 (α4β2) neuronal nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel predominantly expressed in the central nervous system. It represents the highest-affinity binding site for nicotine in the brain and is a key regulator of the mesolimbic dopamine system, which governs reward and reinforcement (UniProt). In the context of nicotine addiction, this receptor undergoes up-regulation following chronic exposure, contributing to the cycle of dependence (PubMed). Therapeutic agents like varenicline target this receptor as partial agonists; they provide a moderate level of receptor activation to alleviate withdrawal symptoms while blocking the reinforcing 'hit' of nicotine from tobacco (StatPearls). Beyond addiction, the α4β2 receptor is implicated in cognitive functions and various neurological disorders, making it a significant focus for drug development in neurology and psychiatry. Mutations in the genes encoding its subunits, CHRNA4 and CHRNB2, are specifically associated with autosomal dominant nocturnal frontal lobe epilepsy (NIH). The receptor's ability to modulate various neurotransmitters, including GABA and glutamate, further underscores its importance in maintaining excitatory-inhibitory balance in the brain.

Other names

α4β2 nicotinic receptorNeuronal acetylcholine receptor subunit alpha-4/beta-2 complexCHRNA4-CHRNB2 receptorNicotinic acetylcholine receptor alpha-4 beta-2 subtype

Varenicline acts as a high-affinity partial agonist at the α4β2 receptor subtype, which stimulates sufficient dopamine release to reduce withdrawal symptoms while simultaneously acting as an antagonist to block the reinforcing effects of nicotine (PubChem, StatPearls).